US4050241003 - Common Stock
HAEMONETICS CORP/MASS
NYSE:HAE (12/20/2024, 8:16:07 PM)
After market: 75.44 0 (0%)75.44
-1.46 (-1.9%)
Haemonetics Corp. engages in the development and distribution of hematology products and solutions. The company is headquartered in Boston, Massachusetts and currently employs 3,657 full-time employees. The firm is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Its technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment includes blood collection and processing devices and disposables for red cells, platelets and whole blood. The Company’s Hospital segment consists of Interventional Technologies, which includes vascular closure devices and sensor-guided technologies, and Blood Management Technologies, which includes devices and methodologies for measuring coagulation characteristics of blood, and blood transfusion management software, among others.
HAEMONETICS CORP/MASS
125 Summer Street
Boston MASSACHUSETTS 02110
P: 17818487100
CEO: Christopher A. Simon
Employees: 3657
Website: https://www.haemonetics.com
For those who appreciate growth without the sticker shock, HAEMONETICS CORP/MASS (NYSE:HAE) is worth considering.
/PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better...
/PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2025, which ended September 28, 2024,...
Here you can normally see the latest stock twits on HAE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: